Feds Clear Velocity Laser System
The new XTRAC Velocity excimer laser system received marketing clearance by the Food and Drug Administration. The system, designed and manufactured by PhotoMedex, Incorporated is indicated to treat patients with vitiligo, leukoderma, atopic dermatitis, and psoriasis. PhotoMedex issued a press release describing the product approval.
The tool is an updated version of the earlier XTRAC Ultra that is both faster and more powerful. The XTRAC delivers the greatest amount of UV power among all the medical excimer lasers currently available on the market. The additional power does not diminish any of the clinical reliability or efficacy associated with the company’s previously approved system.
The device delivers treatment at a rate three times faster compared to the XTRAC ULTRA. As such, it provides an appealing alternative treatment for patients with psoriasis. Most currently available approaches are often costly, time consuming, and carry a significant side effect profile.
An additional benefit of the XTRAC Velocity for this indication is that potential systemic effects are limited. These all create an improved therapeutic modality for patients with moderate to severe psoriasis over less than 20 percent of body surface area in which NB-UVB or PUVA would be indicated.
The XTRAC Ultra was the first FDA-approved excimer laser indicated to treat patients with psoriasis. That system generates 308nm UV-B energy. Psoriasis is the second most common skin disorder across the U.S.
May 15, 2008 Related topics: Product Approval & Certification, Dermatology